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Introduction
During the putative "implantation window", a period
of maximal endometrial receptivity that spans 7-9 days
after ovulation, a series of changes on the structural
and molecular level occur that render the endometrium
susceptible to implantation for the human embryo [1].
There are number of cytokines, adhesion molecules
and receptors that possibly might play a role in
increasing the receptivity of the endometrium, howev-
er the exact "composition" needed for implantation to
occur is not known [1-3].
The TGFβ superfamily comprises at least 42 dis-
tinct mammalian dimeric proteins, that share a similar
structure [4].
These are divided into two subfamilies, the TGFβ
(activin) nodal subfamily and second subfamily
including bone morphogenetic protein, müllerian
inhibitory substance, and growth and differentiation
factor [2].
The TGFβ [1-3] are each synthesized as a large
precursor molecule from which a propeptid must be
cleaved. After secretion, most TGFβ is stored bound to
extracellular matrix components as a complex of
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TGFβ, propeptide and a peptide called latent TGFβ -
binding protein. Release of active TGFβ from the
complex is a critical regulatory step [5]. Many mem-
bers of the TGFβs are expressed by human endometri-
um at different stages of menstrual cycle. The three
TGFβ isoforms have been localized to both epithelial
and stromal cells [6] with TGFβ2 staining being more
intense in the stroma while TGFβ - 1 and - 3 is of equal
staining intensity in stromal and epithelial cells [7].
Cyclical changes in expression level are not evident
for TGFβ1 and TGFβ2, only TGFβ3 varies across the
cycle, with higher expression level during the late
secretory phase [2].
The production and secretion of TGFβ by epithelial
cells in the secretory phase suggests a role in the
preparation of the endometrium for implantation.
TGFβs may play role in human implantation via their
stimulation of fibronectin or vascular endothelial
growth factor production [8] or by promotion of adhe-
sion of trophoblast cells to the [9]. 
More recently it has been shown, that both TGFβ1
and activin A enhance the production of the pro-
implantatory cytokine, leukemia inhibitory factor in
endometrial cells [10] and have profound effects on
ECM production and degradation of enzymes [11]. In
addition retroviral overexpression of TGFβ antagonist
in the mouse uterus in the preimplantation phase
reduces the number of implantation sites [12]. Also its
abnormally elevated expression was observed in
human endometrium during the receptive phase in
women suffering from infertility [12].
In the recent years much attention was given to
extracellular matrix. It is known, that improper
turnover of endometrial extracellular matrix is associ-
ated with disturbances of implantation and functional
bleeding. Studies regarding the MMP2 gene expression
and activity of MMP2 in the implantation window have
shown a higher expression and activity of MMP2 in
women with impaired fertility [13,14].
Our current study is based on working model
hypothesis that disturbances in endometrial extracellu-
lar matrix and dysregulated expression of TGFβs genes
during the implantation window might be a cause of
impaired reproduction. To further test this hypothesis,
we examined the expression of TGFβ2 and MMP2,
MMP9 and TIMP1 in normal human endometria and in
the endometria of women with idiopathic infertility
and unexplained recurrent fetal loss.
Materials and methods
Patients. Endometria have been harvested from 60 women in
reproductive age. Twenty-eight patients with idiopathic infertility,
sixteen patients with unexplained recurrent miscarriage and sixteen
control women were enrolled in this study. Infertile women had
undergone a standard panel of tests that included hysterosalpin-
gography, hormonal profiles and semen analysis. Women with
recurrent miscarriage were evaluated for the presence of antiphos-
pholipid antibodies, karyotype anomalies and uterine malforma-
tion. The control group comprised of fertile women (at least one
live birth, no miscarriages, with regular menses) who were admit-
ted for non-endometrial associated diseases (e.g. benign ovarian
cysts or myoma). Exclusion criteria included patients receiving
hormonal replacement therapy, patients using intrauterine contra-
ceptive devices or oral contraception within last six months and
patients with any major diseases (requiring use of any drugs).
The mean age of infertile women was 29,9 years (±2.6), 31.6
(±4.6) years of age for women with recurrent miscarriages and
41.8 (±5.9) years in control group. Mean number of miscarriages
in the recurrent miscarriage group was 2.7 (range: 2-4) and the
mean duration of infertility was 5.6 years (range: 1-17 years).
Tissue samples. All women underwent serial ultrasound assess-
ments to track follicular growth and the formation of corpus
luteum. During the same cycle, 7-9 days after ovulation (the puta-
tive implantation window) endometrial biopsy by Pipelle or hys-
teroscopy was performed to assess the expression of TGFβ2,
MMP2, MMP9 and TIMP1. Part of the material was assigned to his-
tological assessment according to Noyes and Hertig criteria. The
rest of the material was transferred to RNAlater solution (Qiagen,
Australia) and frozen in -80°C till the isolation of total RNA.
Isolation of the RNA from biopsies was conducted according
to manufacturers instructions, with the Rnaesy Protect Mini Kti
(Qiagen, Australia).  
The evaluation of expression of studied genes was done with
the RT-qPCR in two phases: 
1. Reverse transcription with QuantiTect Reverse Transcription
Kit (Qiagen, Australia). From each sample, a solution contain-
ing no more than 1 μg of isolated RNA had undergone the
reverse transcription reaction according to manufacturers
instructions. The procedure included the elimination of poten-
tial DNA presence. The end result of this phase was comple-
mentary DNA resulting from conversion of mRNA.
2. The real-time PCR: 2 μl of matrix, containing no more than
200 ng of cDNA from the first phase was used to conduct
quantitative analysis of the expression of studied genes with
the use of DyNAmo HS SYBR Green qPCR Kit (Finnzymes,
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Table 1. Sequences of the primers that have been used in the eval-
uation of expression.
Finland). The reaction profile and the mix content was done
according to manufacturers instructions. Primers for the qPCR
reaction were designed with Primer3 software. 
The specificity of oligonucleotides was confirmed using NCBI
BLAST. To assess the efficacy of the qPCR reaction 6 subsequent
10 times dilutions of DNA was used, that was a specific reaction
from the PCR of each studied transcript.
The qPCR was done on Rotor-Gene3000 thermocycler (Cor-
bettResearch, Australia). During the qPCR, after each cycle the
increase in amount of generated product was assessed, and at the
end of a reaction the thermocycler program assigned the fluores-
cence level (Ct) at which the pace of increase of generated product
was logarithmic.
To assess the expression levels and statistical analysis follow-
ing programs were used:
• REST2005 (http://www.gene-quantification.de/download.html
- rest-2005)
• MedCalc (http://www.medcalc.be/) [15].
Results 
TGFβ2 expression in human endometrium 
during the implantation window
The RT-PCR used to analyse TGFβ2 expression in
endometrial RNA samples revealed that in endometria
from women with idiopathic infertility TGFβ2 expres-
sion was 2.8 fold higher than in endometria from con-
trol group (Fig. 1).
Similarly TGFβ2 expression was 2.1 fold higher in
endometrial samples from women with unexplained
recurrent miscarriage compared to the control group
(Fig. 2). Overexpression of TGFβ2 was found in 59%
of endometria from women with infertility and in 64%
of endometria from women with recurrent pregnancy
145Expression of TGF and MMP genes in endometria 
Fig. 1. The relative TGFβ2 expres-
sion in idiopathic infertility group.
Boxes represents the interquartile
range, or the middle 50% of obser-
vations. The dotted line represents
the median gene expression.
Whiskers represent the minimum
and maximum observations.
Fig. 2. The relative TGFβ2 expres-
sion in unexplained miscarriage
group. Boxes represents the
interquartile range, or the middle
50% of observations. The dotted
line represents the median gene
expression. Whiskers represent the
minimum and maximum observa-
tions.
loss compared to the results achieved in control group.
Unfortunately there was no statistically significant dif-
ferences.
MMP2, MMP9, TIMP1 expression in human
endometrium during the implantation window
The RT-PCR studies of MMP2, MMP9 and TIMP1
expression in endometrial samples revealed no signif-
icant differences in their expression between the study
groups and control group (Fig. 1 and 2).
However MMP2, MMP9 and TIMP1 expression in
endometria harvested from women suffering from
idiopathic infertility compared to endometria from
women without reproductive disorders was 1.3, 5.2
and 3.9 fold higher, respectively. Higher MMP2,
MMP9, and TIMP1 expression than in control group
was observed in endometria harvested from women
with infertility (58%, 75% and 92% higher, respec-
tively). Also the expression of MMP9 and TIMP1 in
endometrial samples collected from women with
unexplained recurrent miscarriage compared to
endometrial samples in control group was 2.4 and 3.8
higher, respectively. We found overexpression of
MMP9 and TIMP1 in 63% and 88%, respectively, in
endometrial samples from women with recurrent preg-
nancy loss compared to control group. 
Although MMP2 expression in endometrial sam-
ples didn't differ between unexplained miscarriage and
control group, there was a higher MMP2 expression in
43% of endometrial samples from unexplained miscar-
riage group.
The correlation between TGFβ2, MMP2,
MMP9 and TIMP1 expression  
There was a statistically significant negative correla-
tion between TGFβ2 and MMP9 expression in
endometria from women in control group (Fig. 3),
which means, that a higher TGFβ2 expression was
accompanied by lower MMP9 expression. In both
studied groups we have not been able to show any cor-
relation between expression of TGFβ2 and MMP2, nor
between MMP9 and TIMP1.  
Discussion
While many techniques have been developed that are
used to diagnose different causes of impaired fertility
still in the etiology of about 50% of recurrent miscar-
riages and 10% of infertility remains unexplained.
Many authors tried to explain the etiologies of idio-
pathic infertility and recurrent miscarriage by endome-
trial disturbances both at the tissue and also molecular
level [16-18].
It is becoming increasingly clear, that transforming
growth factor beta (TGFβ is involved in cellular pro-
liferation and differentiation, extracellular matrix
modification, tissue remodeling, angiogenesis and
decidualization of uterine endometrium during the
implantation [19].
All three isoforms of TGFβ have been localized in
rodent and human endometrial epithelium and stroma.
It has been shown, that TGFβs modulate maternal
immunotolerance during implantation and regulate in
vitro several molecules related to implantation as
VEGF, IGFBP1, LIF and MMP9 [2,20]. A role for
TGFβ in the modulation of endometrial receptivity in
monkey has also been reported [21].
Our RT-PCR investigation showed trend for higher
expression of TGFβ2 in endometrial samples from
women with idiopathic infertility and unexplained
recurrent miscarriages compared to endometria from
control group, but we didn't found any statistically sig-
nificant differences. Kothapalli et al. [22] identified
ebaf/lefty - a novel human gene of the TGFβ super-
family during a search for genes highly expressed dur-
ing the non-receptive phase in human endometrium.
Lefty proteins were present in low amounts during the
receptive phase in the endometria and sera of normal
fertile women, but were abundant in the endometria of
a number of infertile patients subjects during the
receptive phase of the cycle [23]. The authors specu-
lated, that successful implantation occurs in the pres-
ence of a low level of ebaf protein in human
endometrium, and that a high level of ebaf would be
associated with infertility. In their study in over 50%
of endometria from infertile patients, a mRNA that
hybridized with full-length ebaf cDNA was up-regu-
lated during the endometrial receptivity period. The
infertility in these women was associated with
endometriosis, polycystic ovary syndrome, bilateral
tube occlusion, anovulatory cycle, luteal phase defect,
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Fig. 3. Correlation between MMP9 and TGFβ2 expression in con-
trol group.
premature ovarian failure and habitual abortion. In
some women, the underlying reason of infertility
remained unknown.
In our study only patients with unexplained infer-
tility were included. In 59% of their endometria we
have observed higher TGFβ2 expression than in con-
trol group. Also in 64% of endometria from women
with unexplained recurrent miscarriages we have
noticed a higher TGFβ2 expression than in endometria
from women in control group.
It has been known, that nearly 50% of early preg-
nancy losses occur when implantation occurs after
postovulatory day 10, when the ebaf protein is rela-
tively abundant in endometrium [24]. These data and
our observation can suggest, that dysregulated TGFβs
gene expression might be a contributing factor leading
to the impairment of implantation.
Lately much attention was paid to the role of
MMPs for endometrial receptivity and the implanta-
tion process. Expression of genes taking part in the
production and degradation of endometrial extracellu-
lar matrix in women with unexplained infertility and
recurrent miscarriages was the subject of studies from
Jokimaa et al. [14]. These author have observed high-
er mRNA level for collagen type 1, MMP2 and
catepsin H in studied patients compared to control
group. Compared to normal endometria, from control
group, in our own RT-PCR study we have observed
higher MMP2 expression in 58% endometria from
women with idiopathic infertility and only in 43%
endometria from women with unexplained recurrent
miscarriages. These data can lead to the conclusion,
that the extracellular matrix participate in the endome-
trial receptivity and that the imbalances in the extra-
cellular matrix might offer explanation for same case
of unexplained infertility and recurrent miscarriages.
Our results regarding MMP9 and TIMP1 mRNA
expression in endometrium during the mid-luteal
phase in patients with idiopathic infertility differ from
results in Wu and Zhon study [25]. While these authors
have notice significantly lower expression of MMP9
and TIMP1 mRNA in endometrium from women with
idiopathic infertility, we have observed a trend for
higher expression of these molecules, however without
statistical significance. We have also found in endome-
tria from women with unexplained recurrent miscar-
riage a higher expression of endometrial MMP9 and
TIMP1 (63% and 88%, respectively) compared to con-
trol group. Bany et al. [26] have shown significantly
higher content of MMP9 mRNA in stimulated decidu-
alization compared with non-stimulated one in the
horn of mouse uterus. In our previous study [27] we
have observed a lower MMP9 and TIMP1 concentra-
tion in uterine fluid collected from women with idio-
pathic infertility and women with unexplained cause
for recurrent miscarriage than in controls. These dis-
cordance can be explained by hypothetic disturbances
between modules expression and their secretion and
transport.
Fact, that decasualization also occurs in the pres-
ence of inhibitors, points to a conclusion, that MMPs
are not indispensable able for endometrial transforma-
tion. It has already been mentioned above, that TGFβ1
has profound effect on ECM production and degrada-
tion of enzymes [11]. To support this hypothesis we
have found statistically negative correlation between
the TGFβ2 and MMP9 expression but only in endome-
tria from control group. 
Also Tabibzadeh et al. [23] have found, that ebaf
up-regulates the expression of matrix metallopro-
teinase -3 and -7, therefore they my be involved in tis-
sue shedding. 
The present investigations suggest that dysregulat-
ed TGFβ2, MMP2, MMP9 and TIMP1 expression are
associated with infertility and early pregnancy loss.
However the exact mechanism of how overexpression
of endometrial TGFβs and MMPs interferes with
implantation may be more complex.
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